How are energy investors positioned?
NASHVILLE, Tenn. - HCA Healthcare, Inc. (NYSE: NYSE:HCA), a leading healthcare provider with a market capitalization of $78.5 billion and annual revenue of $70.6 billion, announced today that its subsidiary, HCA Inc., is planning to offer senior notes. According to InvestingPro analysis, the company maintains a strong financial health score, supporting its debt-raising capabilities. The terms, including interest rate, maturity, and principal amount, will be determined based on current market conditions at the time of pricing. The company intends to use the net proceeds for general corporate purposes, which may encompass repaying existing or future senior credit facility borrowings. With a healthy free cash flow yield of 7% and trading below its Fair Value, HCA demonstrates solid fundamentals. Discover more detailed financial insights and 12 additional ProTips with an InvestingPro subscription.
Joint book-running managers for the offering include BofA Securities, Inc., Barclays (LON:BARC) Capital Inc., Citigroup (NYSE:C) Global Markets Inc., J.P. Morgan Securities LLC, Mizuho (NYSE:MFG) Securities USA LLC, and Wells Fargo (NYSE:WFC) Securities, LLC. The sale of these senior notes will be conducted under an effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC).
The offering will be made to potential buyers via a preliminary prospectus supplement and an accompanying prospectus. Interested parties can obtain these documents from any of the joint book-running managers by request via email, telephone, or by visiting the SEC’s website for an electronic copy.
HCA Healthcare has made it clear that this press release is not an offer to sell or a solicitation to buy the senior notes or any other security. The sale of the notes will not be conducted in jurisdictions where such activity would be unlawful prior to registration or qualification under the securities laws of those jurisdictions.
The press release contains forward-looking statements that are not purely historical, reflecting management’s current expectations about the use of proceeds from the offering. These statements are subject to various risks and uncertainties, and actual results could differ materially from those projected. Currently trading at a P/E ratio of 14.37 with a modest dividend yield of 0.91%, HCA’s comprehensive financial analysis is available through the Pro Research Report, along with expert insights for over 1,400 US stocks on InvestingPro. Risks and uncertainties that could affect the company’s business and operations have been detailed in the "Risk Factors" and "Forward-Looking Statements" sections of HCA’s Annual Report on Form 10-K filed with the SEC on February 14, 2025, and other filings.
The information presented in this article is based on a press release statement from HCA Healthcare.
In other recent news, HCA Healthcare has been the focus of several analyst notes. Cantor Fitzgerald maintained an Overweight rating on HCA Healthcare with a price target of $405, citing confidence in the company’s projected EBITDA for 2025. In contrast, Bernstein SocGen Group raised its price target for HCA to $342 from $331, following the company’s fourth-quarter results for 2024, which reported an adjusted EBITDA of $3,712 million and revenues meeting expectations at $18.3 billion.
Mizuho Securities reiterated its Outperform rating on HCA with a steady price target of $425, despite an adjusted EBITDA miss in the company’s recent earnings report. The firm believes that demand for HCA’s services remains robust, as indicated by a capacity utilization of 71.1% during the quarter. TD Cowen kept its Buy rating on HCA but reduced the price target to $377 from $440 following the company’s fourth-quarter 2024 financial report, which showed a modest outperformance in revenue and EBITDA.
Lastly, RBC Capital Markets adjusted its price target for HCA to $384 from $405, while maintaining an Outperform rating. The adjustment was due to discussions about the quality of HCA’s fourth-quarter earnings, which were influenced by Direct Patient Payment dynamics and hurricane disruptions. These recent developments provide a snapshot of the various perspectives and expectations analysts have for HCA Healthcare’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.